A Possible Therapeutic Role for Adenosine During Inflammation
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 33
- 试验地点
- 1
- 主要终点
- Hemodynamics; heart rate variability
研究概览
简要总结
The adenosine receptor is known for its anti-inflammatory actions and could therefore be a potential target in the treatment of sepsis and septic shock. Stimulation of the adenosine receptor could potentially lead to a decrease in inflammation and tissue damage.
Under normal conditions adenosine is formed either by an intracellular 5'nucleotidase, which dephosphorylates AMP, or by the hydrolysis of S-adenosylhomcysteine by hydrolase. An alternative pathway of AMP degradations is provided by the cytosolic enzyme AMP deaminase (AMPD), which catalyses the irreversible deamination of AMP to inosine monophosphate and ammonia.
In humans four AMPD isoforms have been described, named after the source from which they were initially purified; M (muscle), L (liver), E1 and E2 (erythrocyte), encoded by AMPD1, AMPD2 and AMPD3. Approximately 15-20% of Caucasian and African American individuals are heterozygous or homozygous for the 34C>T variant of AMPD1.
We hypothesize that healthy volunteers who have the polymorphism for AMPD1 have a less severe inflammatory response to LPS and show less (severe) organ failure. This hypothesis is based on the expected higher levels of adenosine in patients with the AMPD1 polymorphism. This hypothesis is strengthened by the fact that patients with coronary artery disease and the AMPD1 polymorphism show improved cardiovascular survival (Anderson JL et al. J Am Coll Cardiol 2000; 36: 1248-52) possibly based on higher adenosine levels by reduced AMPD activity. Furthermore the polymorphism predicts improved clinical outcome in patients with heart failure (Loh E et al. Circulation 1999) also based on a hypothetical elevation of adenosine.
We hypothesize that:
The C34T-polymorphism of the enzyme AMP-deaminase leads to a decreased inflammatory respons and thereby a decrease of LPS-induced tissue damage.
A second hypothesis is based on the antagonism of the adenosine receptor, by caffeine;
Antagonism of the adenosine receptor by caffeine leads to an increased LPS-induced inflammatory reaction and an increase in (subclinical) tissue damage?
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 35 Years(Adult)
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy male volunteers
排除标准
- •Drug-, nicotine-, alcohol abuses
- •Tendency towards fainting
- •Relevant medical history
研究组 & 干预措施
1
Endotoxin and AMPD1 polymorphism
干预措施: AMPD1 polymorphism (Genetic)
2
Endotoxin and intervention with caffeine
干预措施: Caffeine infusion (Drug)
3
Endotoxin combined with placebo
干预措施: placebo (Drug)
结局指标
主要结局
Hemodynamics; heart rate variability
时间窗: 24 hrs after LPS administration
Markers of Inflammation
时间窗: 24 hrs after LPS administration
Cytokines
时间窗: 24 hrs after LPS administration
Sensitivity to norepinephrine
时间窗: 24 hrs after LPS administration
Endothelial-dependent and independent vasorelaxation
时间窗: 24 hrs after LPS administration
Mediators of Vascular reactivity
时间窗: 24 hrs after LPS administration
Markers of endothelial damage and circulating endothelial cells
时间窗: 24 hrs after LPS administration
Urinary excretion of markers of renal injury
时间窗: 24 hrs after LPS administration
Neurologic testing
时间窗: 24 hrs after LPS administration
Adenosine and related nucleotide concentrations.
时间窗: 24 hrs after LPS administration
Additional blood samples will be drawn for measurement of: TLR-expression, Genetics; micro array analyses and determination of intercellular signalling pathways.
时间窗: 24 hrs after LPS administration
次要结局
未报告次要终点
